Inflammation is a balanced physiological response – the body needs it to eliminate invasive organisms and foreign irritants, but excessive inflammation can harm healthy cells, contributing to aging and chronic diseases. To help keep tabs on inflammation, immune cells employ a molecular machine called the NLRP3 inflammasome. NLRP3 is inactive in a healthy cell, but is switched “on” when the cell’s mitochondria (energy-generating organelles) are damaged by stress or exposure to bacterial toxins.
However, when the NLRP3 inflammasome gets stuck in the “on” position, it can contribute to a number of chronic inflammatory conditions, including gout, osteoarthritis, fatty liver disease and Alzheimer’s and Parkinson’s diseases. In a new mouse study, researchers at University of California San Diego School of Medicine discovered a unique approach that might help treat some chronic inflammatory diseases: force cells to eliminate damaged mitochondria before they activate the NLRP3 inflammasome.
The study, published April 11, 2019 by Cell Metabolism, was led by senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology and Ben and Wanda Hildyard Chair for Mitochondrial and Metabolic Diseases at UC San Diego School of Medicine, and first author Elsa Sanchez-Lopez, PhD, a senior postdoctoral researcher in Karin’s lab.
In a 2018 study published in Nature, Karin’s team had shown that damaged mitochondria activate the NLRP3 inflammasome. The researchers also found that the NLRP3 inflammasome is de-activated when mitochondria are removed by the cell’s internal waste recycling process, called mitophagy.
“After that, we wondered if we could reduce harmful excess inflammation by intentionally inducing mitophagy, which would eliminate damaged mitochondria and should in turn pre-emptively inhibit NLRP3 inflammasome activation,” Karin said. “But at the time we didn’t have a good way to induce mitophagy.”
More recently, Sanchez-Lopez was studying how macrophages regulate their uptake of choline, a nutrient critical for metabolism, when she discovered something that can initiate mitophagy: an inhibitor of the enzyme choline kinase (ChoK). With ChoK inhibited, choline is no longer incorporated into mitochondrial membranes. As a result, the cells perceive the mitochondria as damaged, and cleared them away by mitophagy.
“Most importantly, by getting rid of damaged mitochondria with ChoK inhibitors, we were finally able to inhibit NLRP3 inflammasome activation,” Karin said.
To test their new ability to control NLRP3 inflammasome in a living system, the researchers turned to mice. They discovered that treatment with ChoK inhibitors prevented acute inflammation caused by uric acid (accumulation of which triggers gout flares) and a bacterial toxin.
By several measures, ChoK inhibitor treatment also reversed chronic inflammation associated with a genetic disease called Muckle-Well Syndrome, which is caused by mutations in NLRP3 genes. One such measure is spleen size – the larger the spleen, the more inflammation. The spleens of Muckle-Well Syndrome mice are on average twice as large as normal mice, but their spleen sizes normalized after ChoK inhibitor treatment.
NLRP3 inflammasome promotes inflammation because it triggers the release of two very potent pro-inflammatory molecules called cytokines: interleukin (IL)-1? and IL-18. According to Karin, there are existing drugs that can block IL-1?, but not IL-18. ChoK inhibitors, his team found, can reduce both cytokines.
“There are several diseases, including lupus and osteoarthritis, whose treatment will likely require dual inhibition of both IL-1? and IL-18,” Karin said.
The Latest on: Chronic inflammatory disease
via Google News
The Latest on: Chronic inflammatory disease
- Immunotherapies, new gut peptides show promise for cardiometabolic diseaseson December 5, 2021 at 5:08 am
Emerging data suggest immunotherapies and novel peptides that target gut inflammation could serve as complementary agents to available diabetes drugs to more effectively target cardiometabolic ...
- Colorectal cancer surveillance in inflammatory bowel disease: The search continueson December 4, 2021 at 6:12 pm
Patients with inflammatory bowel disease (IBD) are at increased risk for colorectal cancer (CRC). Risk factors for the development of CRC in the setting of IBD include disease duration, anatomic ...
- The Anti-Inflammatory Diet Was Just Linked to a Lowered Risk of Dementia and Cognitive Declineon December 4, 2021 at 9:00 am
A new anti-inflammatory diet study indicates that those who consume more inflammatory foods have an increased risk of developing dementia.
- Review Explains Role of IL-11 in Inflammatory Diseaseson December 3, 2021 at 4:36 pm
Circulating Interleukin-11 is difficult to detect in healthy individuals, but when it is present in various inflammatory diseases, it has an elevated present in affected tissues, according to a ...
- Crohn’s disease: Two chronic symptoms warning you may have the painful conditionon December 1, 2021 at 5:46 am
CROHN'S disease is a painful inflammatory condition which presents a variety of unusual symptoms. What are the two commonly reported signs?
- Opportunities to target mast cells in inflammatory diseases expandon November 30, 2021 at 4:00 pm
Drugs that target mast cells could provide novel options to treat disorders involving chronic allergic inflammation.
- Biomica Reports Positive Results from Pre-Clinical Studies in its Inflammatory Bowel Disease (IBD) Programon November 30, 2021 at 3:00 am
Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
- Stem cell memories may drive wound repair, and also chronic diseaseon November 29, 2021 at 1:17 pm
A trifling paper cut is a site of frenzied activity. Within it, a squad of epidermal stem cells briskly regenerate to patch up the wound. A closer inspection of this war-torn swath of epidermis will ...
- Therapeutic target identified to treat chronic obstructive pulmonary diseaseon November 26, 2021 at 4:08 am
New hope has emerged for people with the debilitating and often deadly chronic obstructive pulmonary disease, with scientists discovering a new therapeutic target that may help to design future ...
- Researchers find new link between a disrupted body clock and inflammatory diseaseson November 24, 2021 at 7:13 am
New research from RCSI has demonstrated the significant role that an irregular body clock plays in driving inflammation in the body's immune cells, with implications for the most serious and prevalent ...
via Bing News